IKCS: Europe

22-24 April 2022

Hilton Antwerp Old Town, Antwerp, Belgium

Important Dates

Review the important dates below for 2022 IKCS: Europe

Abstract Submissions OpenMid-December 2021
Program At a Glance AvailableLate December 2021
Program Details and Speakers ReleasedEarly February 2022
Registration OpensFebruary 2022
Abstract Submission Deadline
(all complete Regular, TPS, and Case Report submissions, and all LBA Placeholders due at this time)
February 2, 2022 at 23:59 GMT
LBA Submission Deadline (LBA Placeholder required by February 2 deadline)February 28, 2022 at 23:59 GMT
Abstract Notifications Sent to Lead AuthorsLate February 2022
Abstract Titles ReleasedMid-March 2022
Abstract Withdrawal Deadline
(Withdrawal requests must be submitted by the Lead Author to [email protected])
March 11, 2022
Early Registration DeadlineMarch 23, 2022 at 23:59 GMT
Abstracts ReleasedApril 18, 2022
Meeting DatesApril 22, 2022- April 24, 2022

Registration and Hotel Information

Registration for 2022 IKCS: Europe will open in February 2022. Additional information on Registration Rates and Categories as well as links and instructions for booking hotel will be provided in February 2022.


Review the 2022 IKCS: Europe Program at a Glance. Additional information will be released in early February 2022.

Session topics will include:

  • Award Lectures- Urology and Oncology
  • Basic Science in RCC
  • Biomarkers in RCC
  • Diagnostics and Screening
  • Keynote Lecture
  • Oral Abstract Session
  • Patient Considerations
  • The Role of Radiation Therapy in the Management of RCC
  • Selecting Therapy for non-clear cell RCC Subtypes
  • Surgical Approaches in Kidney Cancer
  • Systemic Therapy: Selecting First-line Therapy and Later-line Therapy
  • Therapeutic Management
  • WoodFire (WoodFire is an exciting chance to watch clinicians debate the various treatment options for presented oncology cases. It’s the fiercest tumor board you’ll ever see!)

The 2022 Program will also feature in-person and virtual networking opportunities including:

  • Meet the Experts Networking
  • Women in Renal Cell Carcinoma Networking
  • Dedicated Poster Sessions and Guided Poster Walks
  • Exhibit Hall
  • Receptions and more!


Abstract Submission Guidelines

Follow the guidelines below to submit an abstract to 2022 IKCS: Europe.

  • All submitters are required to create a free account with Submittable or login with an existing account to access the abstract submission form.
  • Important Deadlines:
    • Abstract Submission Deadline (all submissions including LBA placeholder submissions due at this time): February 2, 2022 at 23:59 GMT
    • LBA Final Data Submission Deadline (final data, results, and conclusions for LBA placeholder submissions due at this time): February 28, 2022 at 23:59 GMT
      • Additional instructions will be sent to lead authors to complete their LBA submissions.
    • Abstract Notifications will be sent to lead authors in late February 2022
    • LBA lead authors will receive abstract notifications in early March 2022
  • Abstract Submission Types:
    • Regular Abstract (All research types and summaries of new, ongoing, and updated research relating to kidney cancer will be considered)
    • Trials in Progress Abstract (All research types that are open, enrolling, ongoing, and have not reached pre-specified endpoints for analysis.)
    • Late-breaking Data Submission Abstract (Phase I, II, III, or IV trials and original, high-impact research that could impact practice and standard of care)
    • Case Report (A report of the diagnosis, treatment, and follow up of an individual patient)
  • Abstract Sections:
    • Abstract Title: The title should objectively describe the study and should not include proprietary drug names.
    • Abstract Text: The abstract text should be no more than 300 words including the title and abstract body. Word count does not apply towards spaces, authors, and affiliations. All abstracts should be structured into four sections:
      • Background
      • Methods
      • Results
      • Conclusions
    • Optional Abstract Graph, Illustration, or Table: One brief graph, illustration, or table is permitted.
    • Authors: The maximum number of authors permitted is 20. Pharmaceutical industry authors are allowed to present abstracts in non-CME sessions (Poster Sessions). If an abstract is selected for presentation in a CME-session, and the presenter has financial relationships with ACCME-defined ineligible companies, an alternate presenter must be identified. A non-named author can present a poster if written permission is provided by the lead author to [email protected].
Abstract Submission Categories

Abstracts in the following categories will be considered for presentation:

  • Basic Science
  • Disparities in Cancer, Care, and Access
  • Diagnostics
  • Imaging
  • Impact of COVID-19
  • Patient-reported Outcomes
  • Prevention and Screening
  • Quality of Care and Quality Improvement
  • Real-World Evidence
  • Treatment Toxicities and Symptom Management
  • Therapeutics
  • Tumor Biology, Biomarkers, and Pathology
  • Other
Late-breaking Data Submission Guidelines

Abstracts submitted in this category are Phase I-IV trials, or original research that could impact practice and standard of care. LBA Abstracts should be studies where results and conclusions are not yet available by the February 2 deadline, but will be available by the February 28, 2022 23:59 GMT deadline.

Abstracts submitted in this category must have a placeholder submission (all components except for Results and Conclusions sections) received by the February 2, 2022 23:59 GMT abstract submission deadline.

Lead authors will receive separate instructions to complete LBA placeholder submissions by the February 28, 2022 23:59 GMT deadline.

Trials in Progress Abstract Submission Guidelines

Abstracts submitted in this category are ongoing and should not include data, results, nor conclusions.

TPS abstracts are open, enrolling, or ongoing and have not reached any protocol-specific endpoints for analysis, and consequently will only require the completion of the Background and Methods sections.

Abstracts in all phases of clinical research (I, II, III, IV) may be submitted.

Abstract Review and Selection Process

Abstracts will be reviewed by the IKCS: Europe Scientific Program Committee. Abstract notifications will be sent to lead authors in late February 2022.

Abstract-Associated Awards

The IKCS Scientific Program Committee will select authors of high-quality submitted abstracts to receive a merit award for the best original submissions.
*Please note: Trials in Progress presentations will not be eligible to receive a merit award.

  • First place: $500 and complimentary meeting registration
  • Second place: $250 and complimentary meeting registration
  • Third place: $100 and complimentary meeting registration
Abstract Presenter Guidelines

All accepted abstracts and lead authors are encouraged to present in-person at 2022 IKCS: Europe in Antwerp, Belgium. Accepted abstracts will be displayed at the live meeting and electronic versions will be available online.

All Abstract Presenters must register for the conference.

All accepted abstracts will be published in the Kidney Cancer Journal, the official journal of the Kidney Cancer Association.

Additional Abstract Presenter Guidelines will be provided here in February 2022.

Continuing Medical Education (CME) Information

Continuing Medical Education (CME) Information

Jointly provided by The France Foundation and the Kidney Cancer Association.

Target Audience: This educational activity is intended for medical oncologists and urologists who treat patients with kidney cancer. Fellows, trainees, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of kidney cancer are invited to participate.

Statement of need: Education and Interaction surrounding the space of renal cell carcinoma are paramount to improving patient care. This program is targeted to physicians, advocates, researchers, and care team members to help promote learning and collaboration for advancement in the renal cancer space.

Educational Learning Activity Objectives: Upon completion of this course, the participants should be able to:

  • Characterize the various therapies currently available for locally advanced and metastatic renal cell carcinoma
  • Identify the novel approaches to non-clear RCC patient management
  • Understand the role of the tumor microenvironment in kidney cancer
  • Discuss how to design biomarker driven clinical trials in kidney cancer

Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the Kidney Cancer Association. The France Foundation is accredited by ACCME to provide continuing medical education for physicians.

Credit Designation:

Physicians: The France Foundation designates this live activity for a maximum of 14.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

An application has been made to the UEMS EACCME for CME accreditation of this event.

IKCS: Europe Scientific Program Committee

Thank you to our 2022 IKCS: Europe Planners!

Michael Staehler, MD, PhD
Guillermo de Velasco, MD, PhD
Lars Lund, MD, DMSci
Gabriel Malouf, MD, PhD
Thomas Powles, MD, MBBS, MRCP
Samra Turajlic, PhD, MRCP

Sponsorship and Exhibitor Opportunities

Download the 2022 IKCS: Europe Sponsorship Prospectus. Please contact [email protected] for more information.

Faculty Presentation Guidelines

Meeting Format

Meeting Format: 2022 IKCS: Europe will be a hybrid event offering in-person and virtual participation options for meeting attendees. Faculty are expected to attend in-person in Antwerp, however, reasonable adjustments may be considered due to COVID-19 related travel restrictions. Onsite sessions will be live-streamed to virtual attendees.

Conflict of Interest Disclosure and Session Preparation Information

Conflict of Interest Disclosure: Confirmation of any faculty invitation requires agreement to abide by Conflict of Interest procedures in addition to policies set forth by the Kidney Cancer Association, The France Foundation, and the Accreditation Council for Continuing Medical Education (ACCME) for content and presentation. All Faculty are required to submit a full disclosure of financial interests with commercial entities. All Conflict of Interest Disclosures will be reviewed by The France Foundation for final approval and participation in the program. Failure to submit a Conflict of Interest Disclosure will prohibit participation in the program.

Session Preparation: Speakers should upload their presentation slides by March 16, 2022. Slides will be reviewed by Session Chairs/Moderators and CME regulators to ensure compliance with CME guidelines, minimize content overlap between sessions, and help presentations contribute to a cohesive and educational session. Speakers may receive recommendations for slide adjustments. Speakers who are only able to participate virtually will receive instructions to pre-record their presentations prior to the meeting, along with instructions to participate in the live panel Q+A at the end of the session.